REFERENCES
- Bartalena L. Editorial: Glucocorticoids for Graves' ophthalmopathy: How and when. J Clin Endocrinol Metab. 2005a; 90: 5497–5499, [PUBMED], [INFOTRIEVE], [CSA]
- Bartalena L, Marcocci C, Bogazzi F, et al. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med. 1989; 321: 1349–1352, [PUBMED], [INFOTRIEVE], [CSA]
- Bartalena L, Marcocci C, Bogazzi F, et al. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves' ophthalmopathy. J Clin Endocrinol Metab. 2005b; 90: 5321–5323, [CSA], [CROSSREF]
- Bartalena L, Marcocci C, Gorman C A, et al. Orbital radiotherapy for Graves' ophthalmopathy: Useful or useless? Safe or dangerous?. J Endocrinol Invest. 2003; 26: 5–16, [INFOTRIEVE], [CSA]
- Bartalena L, Marcocci C, Pinchera A. Somatostatin analogs for Graves' ophthalmopathy: Do they bounce off like a rubber bullet?. J Clin Endocrinol Metab. 2004; 89: 5908–5909, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: Reality and perspectives. Endocr Rev. 2000; 21: 168–199, [INFOTRIEVE], [CSA], [CROSSREF]
- Burch H B, Wartofsky L. Graves' ophthalmopathy: Current concepts regarding pathogenesis and management. Endocr Rev. 1993; 14: 747–793, [INFOTRIEVE], [CSA], [CROSSREF]
- Cawood T, Moriarty P, O'Shea D. Recent developments in thyroid eye disease. BMJ. 2004; 329: 385–390, [INFOTRIEVE], [CSA], [CROSSREF]
- Dickinson A J, Vaidya B, Miller M, et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2004; 89: 5910–5915, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Gorman C A, Garrity J A, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology. 2001; 108: 1523–1534, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Gorman C A, Garrity J A, Fatourechi V, et al. The aftermath of orbital radiotherapy for graves' ophthalmopathy. Ophthalmology. 2002; 109: 2100–2107, [INFOTRIEVE], [CSA], [CROSSREF]
- Kahaly G J, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab. 2005; 90: 5234–5240, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kahaly G J, Rosler H P, Pitz S, Hommel G. Low- versus high-dose radiotherapy for Graves' ophthalmopathy: A randomized, single blind trial. J Clin Endocrinol Metab. 2000; 85: 102–108, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Krassas G E, Heufelder A E. Immunosuppressive therapy in patients with thyroid eye disease: An overview of current concepts. Eur J Endocrinol. 2001; 144: 311–318, [INFOTRIEVE], [CSA], [CROSSREF]
- Krassas G E. Somatostatin analogs: A new tool for the management of Graves' ophthalmopathy. J Endocrinol Invest 2004; 27: 281–287, [INFOTRIEVE], [CSA]
- Marcocci C, Bartalena L, Marino M, et al. Current medical management of Graves ophthalmopathy. Ophthal Plast Reconstr Surg. 2002; 18: 402–408, [INFOTRIEVE], [CSA]
- Marcocci C, Bartalena L, Rocchi R, et al. Long-term safety of orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab. 2003; 88: 3561–3566, [INFOTRIEVE], [CSA], [CROSSREF]
- Marcocci C, Bartalena L, Tanda M L, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: Results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab. 2001; 86: 3562–3567, [INFOTRIEVE], [CSA], [CROSSREF]
- Marino M, Morabito E, Brunetto M R, et al. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid. 2004; 14: 403–406, [INFOTRIEVE], [CSA], [CROSSREF]
- Mourits M P, van Kempen-Harteveld M L, Garcia M B, et al. Radiotherapy for Graves' orbitopathy: Randomised placebo-controlled study. Lancet. 2000; 355: 1505–1509, [INFOTRIEVE], [CSA], [CROSSREF]
- Perros P, Kendall-Taylor P, Neoh C, et al. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves' ophthalmology. J Clin Endocrinol Metab. 2005; 90: 5321–5323, [INFOTRIEVE], [CSA], [CROSSREF]
- Perros P, Krassas G E. Orbital irradiation for thyroid-associated orbitopathy: Conventional dose, low dose or no dose?. Clin Endocrinol (Oxf). 2002; 56: 689–691, [CSA], [CROSSREF]
- Prummel M F, Terwee C B, Gerding M N, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab. 2004; 89: 15–20, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Prummel M F, Wiersinga W M. Smoking and risk of Graves' disease. JAMA. 1993; 269: 479–482, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Shine B, Fells P, Edwards O M, Weetman A P. Association between Graves' ophthalmopathy and smoking. Lancet. 1990; 335: 1261–1263, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Steinsapir K D, Goldberg R A. Orbital radiation therapy for Graves' ophthalmopathy. Ophthalmology. 2003; 110: 451–452, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Tallstedt L, Lundell G, Torring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992; 326: 1733–1738, [PUBMED], [INFOTRIEVE], [CSA]
- Wiersinga W M. Preventing Graves' ophthalmopathy. N Engl J Med. 1998; 338: 121–122, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wiersinga W M, Prummel M F. Pathogenesis of Graves' ophthalmopathy-current understanding. J Clin Endocrinol Metab. 2001; 86: 501–503, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wemeau J L, Caron P, Beckers A, et al. Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab. 2005; 90: 841–848, [INFOTRIEVE], [CSA], [CROSSREF]